FDA Approves Tryptyr Eye Drops for Treatment of Dry Eye Disease
The FDA has approved Tryptyr, the first eye drop that stimulates nerve activity to rapidly increase tear production, offering new hope for dry eye disease treatment.
The U.S. Food and Drug Administration (FDA) has granted approval to the innovative ophthalmic solution, Tryptyr (acoltremon), developed by Alcon, marking a significant advancement in dry eye disease management. This first-in-class eye drop functions as a TRPM8 receptor agonist, uniquely stimulating corneal sensory nerves to promote natural tear production quickly.
Dry eye disease treatment options have historically faced challenges such as slow onset of relief, limited efficacy, and poor patient adherence. Tryptyr aims to overcome these issues by directly addressing tear deficiency, a fundamental cause of dry eye symptoms.
The approval is supported by the results from two large Phase III clinical trials, COMET-2 and COMET-3, which involved over 930 participants with a history of dry eye. The trials demonstrated that Tryptyr significantly increased tear production as early as the first day of treatment. By day 14, a notable proportion of patients experienced a ≥10-mm increase in natural tear production — 42.6% in COMET-2 and 53.2% in COMET-3 — compared to only 8.2% and 14.4% respectively in the placebo group. These effects persisted through 90 days of treatment.
Common side effects reported in the studies included instillation site pain. Dr. Marjan Farid from the University of California, Irvine, highlighted the importance of new treatment options: "Many patients continue to face challenges with dry eye management, and Tryptyr offers a new approach by directly stimulating tear production."
Alcon plans to launch Tryptyr in the United States during the third quarter of 2025, providing a new option for patients seeking faster and more effective relief from dry eye symptoms.
This approval represents a promising development in ophthalmology, potentially improving quality of life for millions affected by dry eye disease.
(Source: https://medicalxpress.com/news/2025-06-fda-tryptyr-eye-dry-disease.html)
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Lung Cancer Trial Model Promises Faster and More Inclusive Research
The Pragmatica-Lung trial demonstrates a fast, inclusive, and efficient model for lung cancer research, providing valuable insights despite not meeting its primary survival endpoint. This approach could revolutionize future clinical trials in oncology.
Growing Concerns Over Recreational Nitrous Oxide: Brain Damage and Sudden Death Risks Persist Despite Bans
Recreational use of nitrous oxide poses serious health risks including brain damage and death. Despite bans and regulations, availability and misuse continue to rise, especially among youth in the U.S. Learn about the dangers and ongoing efforts to curb this growing threat.
Promising Results from Shortened Immunotherapy Duration for Advanced Melanoma in Clinical Trial
A groundbreaking clinical trial suggests that stopping immunotherapy after one year may be as effective as two years for advanced melanoma, potentially reducing side effects and treatment burden.
RSV Vaccine Linked to Lower Dementia Risk in New Study
A new study highlights that the RSV vaccine Arexvy may reduce dementia risk by 29% within 18 months, adding to evidence that vaccines can have protective effects on brain health.